Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Vifor Pharma's Phase III study on its ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Use of the sucroferric oxyhydroxide binder by Fresenius Medical Care Renal Therapies Group, ...

WALTHAM, Mass., March 31, 2020 /PRNewswire/ -- A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro ® (sucroferric ...

The US Food and Drug Administration (FDA) has approved sucroferric oxyhydroxide (Velphoro, Vifor Fresenius Medical Care Renal Pharma) for treatment of hyperphosphatemia in patients with chronic kidney ...

SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned ...

Regulators in Europe have given the green light to Vifor Fresenius Medical Care Renal Pharma's hyperphosphatemia drug Velphoro. Regulators in Europe have given the green light to Vifor Fresenius ...

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that the US District Court for the District of Delaware issued a judgment in VFMCRP’s favour regarding US patent no. 9,561,251 which covers ...

St. Gallen, Switzerland, 30 April 2021 –Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of ...

A further ANDA patent infringement lawsuit against Teva based on patents no. 10,682,376, no. 10,695,367 and no 11,013,761, all expiring in May 2029 remains pending. “CSL Vifor welcomes the decision by ...